The European Medicines Agency extends the shelf life of the antigens used in Strangvac to 28 months.

Stockholm, March 9, 2022 - The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months.

The manufacturing of Strangvac, a vaccine against the highly contagious equine disease strangles, takes place in two steps - first the antigens are produced in a process that yields sufficient antigens for several million doses, then vaccine doses are produced by mixing the antigens with adjuvant and saline. The reconstituted vaccine doses are transferred into vials that are labelled and packaged for sale. The antigens produced in step one can now be used for mixing with adjuvant and saline based upon the new extended shelf life of 28 months from the time of manufacture. The shelf life of the labelled vaccine doses in vials then has a further approved shelf life of 24 months, which is not limited by the shelf life of the antigens.

"This is excellent news as we move towards the launch of Strangvac. The approval of a 28-month shelf life for the antigens in Strangvac provides increased flexibility in the manufacturing process. The antigens in Strangvac are very stable and this approval was expected, but we are delighted that it is now in place" says Dr. Tim Wood, Head of Manufacturing and Regulatory Affairs at Intervacc.

"Our plan for sales of Strangvac® to start in March remains unchanged." said Andreas Andersson, Chief Executive Officer of Intervacc.

 

For more information please contact:  

Andreas Andersson, CEO

Phone: [phone], cell [phone]

E-mail: [e-mail]

 

The information was submitted for publication, through the agency of the contact person set out above on March 9, 2022, 11.20 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, [e-mail], [phone] as Certified Adviser.

 

About equine strangles

Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

 

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [e-mail], Phone: +46 (0)8 - 684 211 10

https://news.cision.com/intervacc/r/the-european-medicines-agency-extends-the-shelf-life-of-the-antigens-used-in-strangvac-to-28-months-,c3521631

https://mb.cision.com/Main/4632/3521631/1546201.pdf

https://news.cision.com/intervacc/i/lntervacc-,c3022056

(c) 2022 Cision. All rights reserved., source Press Releases - English